Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psoriasis (PsO) Clear all
Completed Phase 2 Interventional Results available

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

NCT04718896
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cypress, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Recruiting Phase 1 Interventional

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

NCT06982352
View directory record Official record
Conditions
Atopic Dermatitis (AD), Psoriasis (PsO)
Interventions
LPX-TI641, Placebo
Drug
Lead sponsor
LAPIX Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Fargo, North Dakota • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 22, 2026, 10:30 PM EDT
Recruiting Phase 4 Interventional

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942
View directory record Official record
Conditions
Psoriasis, Overweight or Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Results available

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

NCT04163016
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions
Pharmacokinetics of certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 10:30 PM EDT
Not yet recruiting Not applicable Interventional

The Effects of Audio-Based Therapy on Anxiety in Psoriasis

NCT07390487
View directory record Official record
Conditions
Psoriasis (PsO), Anxiety
Interventions
Music Therapy, Pink Noise
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Terminated No phase listed Observational

A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

NCT06715254
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

NCT06588283
View directory record Official record
Conditions
Psoriasis, Obesity
Interventions
Ixekizumab, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

NCT07648602
View directory record Official record
Conditions
Psoriasis
Interventions
Observational (Non-Interventional) Registry
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2036
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Interventions
Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
1,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Chandler, Arizona • Pheonix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326298
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

NCT03766685
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 22, 2026, 10:30 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab, ustekinumab, placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
6 Years to 17 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
Fountain Valley, California • Los Angeles, California • Northridge, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jul 22, 2026, 10:30 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
74
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Active, not recruiting Not applicable Interventional

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

NCT07221890
View directory record Official record
Conditions
Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Psoriasis (PsO)
Interventions
Offered an academic detailing session, Standard-of-care outreach from the insurance plan
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
1,325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Louisville, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03410992
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study

NCT07615712
View directory record Official record
Conditions
Psoriasis
Interventions
Observational (Non-Interventional) Registry
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 10:30 PM EDT